January 5, 2018 / 12:04 PM / in 9 months

BRIEF-Kala Pharmaceuticals Announces Topline Results For Two Phase 3 Trials Of Kpi-121

Jan 5 (Reuters) - Kala Pharmaceuticals Inc:

* KALA PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FOR TWO PHASE 3 TRIALS (STRIDE 1 AND STRIDE 2) OF KPI-121 0.25% IN DRY EYE DISEASE

* KALA PHARMACEUTICALS INC - KPI-121 0.25% WAS WELL-TOLERATED WITH ELEVATIONS IN IOP SIMILAR TO PLACEBO

* KALA PHARMACEUTICALS INC - IN STRIDE 1 TRIAL, STATISTICAL SIGNIFICANCE WAS ACHIEVED FOR PRIMARY SIGN ENDPOINT

* KALA PHARMACEUTICALS- OCULAR DISCOMFORT SEVERITY AT DAY 15 IN ITT POPULATION SHOWED IMPROVEMENT BUT DID NOT REACH STATISTICAL SIGNIFICANCE IN STRIDE 2

* KALA PHARMACEUTICALS INC - IN STRIDE 2 TRIAL, STATISTICAL SIGNIFICANCE WAS ACHIEVED FOR PRIMARY SIGN ENDPOINT

* KALA PHARMACEUTICALS INC - WILL CONTINUE TO ANALYZE RESULTS OF BOTH PHASE 3 TRIALS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below